In a double-blind within-patient clinical trial in psoriasis, budesonide 0.025% ointment has been shown to be at least as efficient as betamethasone 17-valerate 0.1% ointment. A lower concentration of budesonide ointment, 0.01%, was used for 4 weeks of maintenance treatment. This concentration controlled residual symptoms well in a majority of the patients, thirty-two in number.
Get full access to this article
View all access options for this article.
References
1.
AgrupGBjömbergAElmrosTGrothOHannukselaMLassusASaldeLSkoghMThomsenK (1981) Clinical trial of a potent non-halogenated topical steroid – budesonide. Acta Dermatovener (Stockholm)6, 180.
2.
AgrupGLassusALidénAOsmundsenP ERajkaGSondergaardJ (1978) Classification of modern corticosteroid preparations (in Swedish). Läkartidningen75, 19, 1924.
3.
GruvstadEBengtssonB (1980) A comparison of a new steroid, budesonide, with other topical corticosteroids in the vasoconstriction assay. Drugs in Experimental and Clinical Research6, 5.
4.
LassusASaldeLA double-blind comparison of two topical steroids in psoriasis and eczemas: Budesonide 0.025% ointment and betamethasone-17-valerate 0.1% ointment. (In manuscript).
5.
RyrfeldtÅAnderssonPEdsbäckerS (1980) Liver and skin biotransformation of glucocorticosteroids in hairless mouse, rat and man. In: ‘Abstracts' the 22nd Nordic Conference on Dermatology, Helsinki 1980. Editors: Mustakallio K and Förström L, p 181.
6.
ThalénABrattsandR (1979) Synthesis and anti-inflammatory properties of budesonide. A new non-halogenated glucocorticoid. Arzneimittel Forschung (Drug Research)29, (II), 1687.
7.
WilsonL (1976) The clinical assessment of topical corticosteroid activity. British Journal of Dermatology94, suppl 12, 33.
